The stock of Teligent Inc (NASDAQ:TLGT) is a huge mover today! The stock decreased 1.92% or $0.12 during the last trading session, hitting $6.14. About 242,788 shares traded hands. Teligent Inc (NASDAQ:TLGT) has risen 16.79% since April 6, 2016 and is uptrending. It has outperformed by 14.83% the S&P500.
The move comes after 8 months negative chart setup for the $336.76M company. It was reported on Nov, 8 by Barchart.com. We have $5.28 PT which if reached, will make NASDAQ:TLGT worth $47.15M less.
According to Zacks Investment Research, “Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey.”
More notable recent Teligent Inc (NASDAQ:TLGT) news were published by: Prnewswire.com which released: “Teligent, Inc. Announces Third Quarter 2016 Results” on October 27, 2016, also Marketwatch.com with their article: “Teligent Inc. NASDAQ: TLGT” published on October 29, 2015, Prnewswire.com published: “Teligent, Inc. To Hold Conference Call For 3rd Quarter 2016 Results” on October 14, 2016. More interesting news about Teligent Inc (NASDAQ:TLGT) were released by: Prnewswire.com and their article: “Teligent, Inc. Announces The Opening Of A Product Development Laboratory In …” published on October 11, 2016 as well as Prnewswire.com‘s news article titled: “Teligent, Inc. Announces Health Canada Approval Of Gentamicin Injection USP” with publication date: August 23, 2016.
TLGT Company Profile
Teligent, Inc., formerly IGI Laboratories, Inc., incorporated on August 26, 1977, is a specialty generic pharmaceutical company. Under its own label, the Company markets and sells generic injectable pharmaceutical products in the United States and Canada. It is also marketing over eight generic topical pharmaceutical products and approximately four branded generic pharmaceutical products. The Firm provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. The Firm focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its current contract manufacturing and formulation services business. The Company’s pipeline includes over 30 Abbreviated New Drug Applications (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products. In addition, it has over four abbreviated new drug submissions (ANDS), on file with Health Canada. It holds additional over 40 product candidates at various stages of its development pipeline, approximately 10 of which are on stability testing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.